131I-tositumomab therapy as initial treatment for follicular lymphoma.

By M. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll and 1 more. New England Journal of Medicine, 2005

724 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/376e1c7e7292cc2c4e6c66638f57cdd47efa5816

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. Jacks
2. M. Winslow
3. J. Dahlman
4. R. Langer
5. D. Heller
6. Daniel Anderson
7. Avi Schroeder
8. George W. Pratt

Citations in the corpus

• Treating metastatic cancer with nanotechnology (2011, background): “For instance, 131 I-tositumomab (Bexxar; GlaxoSmithKline) is a combination therapy that involves a radiolabelled CD20-specific antibody for targeting follicular B cell lymphom”